Abstract
Aim: In the recent years, evidences have been accumulated indicating that carcinogen/drug metabolizing genes and DNA-repair genes may play an important role in determining individual susceptibility to cancer & treatment outcomes. Pharmacogenetic variability associated with the drug metabolizing enzymes could be a major determinant of variations in treatment outcomes. The present study was designed to understand effect of Pharmacogenetic variability associated with Cytochrome P4502C19 (CYP2C19) on treatment outcomes in cancer patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
